Summary:
- Researchers have conducted a small-scale clinical trial utilizing CAR-T cell therapy, typically used for cancer treatment, to target and eliminate autoreactive B cells responsible for multiple sclerosis (MS).
- The study demonstrated that a single infusion of these engineered cells resulted in a significant reduction of MS symptoms, suggesting a potential paradigm shift toward curative rather than merely palliative treatments for autoimmune diseases.